Anavex Highlights Role of Sigma-1 Brain Receptor in Alzheimer’s Development

Anavex Life Sciences has published a study demonstrating the sigma-1 receptor’s role in Alzheimer’s disease. The data contained in it supports the New York-based company’s development of compounds stimulating this receptor as a way of treating the illness. The study, “Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.

The Anavex studies have been more than encouraging to this point in time. The company is currently fine-tuning before launching the upcoming phase 2/3 clinical trial. This could be the technology that has evaded Big Pharma for decades.

Disclaimer:

Alzheimer's News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more